1. Home
  2. QSEA vs COYA Comparison

QSEA vs COYA Comparison

Compare QSEA & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QSEA
  • COYA
  • Stock Information
  • Founded
  • QSEA 2024
  • COYA 2020
  • Country
  • QSEA United States
  • COYA United States
  • Employees
  • QSEA N/A
  • COYA N/A
  • Industry
  • QSEA Blank Checks
  • COYA Biotechnology: Pharmaceutical Preparations
  • Sector
  • QSEA Finance
  • COYA Health Care
  • Exchange
  • QSEA Nasdaq
  • COYA Nasdaq
  • Market Cap
  • QSEA 115.3M
  • COYA 107.0M
  • IPO Year
  • QSEA 2025
  • COYA 2022
  • Fundamental
  • Price
  • QSEA $10.12
  • COYA $6.86
  • Analyst Decision
  • QSEA
  • COYA Strong Buy
  • Analyst Count
  • QSEA 0
  • COYA 4
  • Target Price
  • QSEA N/A
  • COYA $16.50
  • AVG Volume (30 Days)
  • QSEA 99.0
  • COYA 52.8K
  • Earning Date
  • QSEA 01-01-0001
  • COYA 08-12-2025
  • Dividend Yield
  • QSEA N/A
  • COYA N/A
  • EPS Growth
  • QSEA N/A
  • COYA N/A
  • EPS
  • QSEA N/A
  • COYA N/A
  • Revenue
  • QSEA N/A
  • COYA $423,452.00
  • Revenue This Year
  • QSEA N/A
  • COYA $40.52
  • Revenue Next Year
  • QSEA N/A
  • COYA N/A
  • P/E Ratio
  • QSEA N/A
  • COYA N/A
  • Revenue Growth
  • QSEA N/A
  • COYA N/A
  • 52 Week Low
  • QSEA $10.03
  • COYA $4.65
  • 52 Week High
  • QSEA $10.58
  • COYA $10.24
  • Technical
  • Relative Strength Index (RSI)
  • QSEA N/A
  • COYA 62.90
  • Support Level
  • QSEA N/A
  • COYA $5.86
  • Resistance Level
  • QSEA N/A
  • COYA $6.28
  • Average True Range (ATR)
  • QSEA 0.00
  • COYA 0.40
  • MACD
  • QSEA 0.00
  • COYA 0.05
  • Stochastic Oscillator
  • QSEA 0.00
  • COYA 97.67

About QSEA Quartzsea Acquisition Corporation Ordinary Shares

Quartzsea Acquisition Corp is a blank check company.

About COYA Coya Therapeutics Inc.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Share on Social Networks: